Mouse line as a model for Peripheral T-cell Lymphoma with GATA3+ features

This technology is a mouse model and murine lymphoma line that allows for the conditional knock-in of the Vav1-Myof1 fusion oncogene in CD4+ T cells.

Unmet Need: In vitro and in vivo models for Peripheral T-cell Lymphoma

Peripheral T-cell Lymphomas (PTCLs) represent a heterogeneous and poorly understood pathological group of non-Hodgkin lymphomas associated with poor prognosis, particularly in those with the GATA3+ subtype. Mutations in the Vav1-Myof1 fusion oncogene can result in PTCL. Animal models are necessary to better understand the role of Vav1-Myof1 and develop targeted treatments for these disorders. However, there are currently few animal models to study PTCL in vivo, and none that look specifically at this oncogene.

The Technology: Conditional knock-in cell and mouse models for Peripheral T-cell Lymphoma

This technology is a mouse model and murine lymphoma line that allows for the conditional knock-in of the Vav1-Myof1 fusion oncogene in CD4+ T cells. It can be used to study PTCL with GATA3+ features and screen targeted treatments. It can also be used to understand the role of Vav1-Myof1 in hematological malignancies and screen potential therapeutics.

Applications:

  • Therapeutic screening for PTCL
  • Research tool for analysis of tumor microenvironment
  • Research tool for analysis of tumor-suppressing agents
  • Research tool for analysis of Peripheral T-cell lymphoma pathogenesis
  • Diagnostic assays for cancers
  • Genetic screening of cancerous mutations

Advantages:

  • Replicates human diseases associated with Vav1-Myof1
  • Creates consistent and reproducible genetic knockouts
  • Knocks out Vav1-Myof1 only in specific cells of interest
  • Provides a model of Peripheral T-cell Lymphoma with GATA3+ features
  • High-throughput platform for disease analysis and drug screening

Lead Inventor:

Teresa Palomero, Ph.D.

Related Publications:

Tech Ventures Reference:

Quick Facts:
Tags
CD4CarcinogenesisGenetic testingHigh-throughput screeningIn vitroLymphomaMurinaeOncogenePathogenesisPrognosisT cellTumors of the hematopoietic and lymphoid tissues
Inventors
Adolfo A. Ferrando M.D., Ph.D.Teresa Palomero Vasquez
Manager
Joan Martinez
Departments
Institute for Cancer GeneticsPathology
Divisions
College of Physicians and Surgeons (CUMC)Columbia University Medical Center (CUMC)
Reference Number
CU23321
Release Date
2023-06-15
Collections
Oncology